TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

K Fizazi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.